Timothy Voorhees
Timothy Voorhees
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder; EBV-Related Post-Transplant Lymphoproliferative Disorder; Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder; Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder; Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder; Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder | Recruiting | Phase 1 | 2026-09-24 | NCT06672705 | |
| Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder; Polymorphic Post-Transplant Lymphoproliferative Disorder | Recruiting | Phase 2 | 2026-04-14 | NCT05786040 |